Home Featured Page 223

Featured

Latest

Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial

Three Brain Injuries, One Iboga Protocol, and What It Tells Us

The War on Drugs Was Never About Drugs. Psychedelic Healing Must Reckon With That.

A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race

Complete Results from Red Light Oregon Market Research in Oregon Show...

Cybin Granted DEA Schedule I Manufacturing License

MINDCURE Provides Update on Studies and Clinical Trials

The Missing Mushroom: Psychedelic Science and the Future of Psilocybin

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy...

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker...

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion...

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development...

Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development...

EDITOR PICKS

Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA...

Three Brain Injuries, One Iboga Protocol, and What It Tells Us

The War on Drugs Was Never About Drugs. Psychedelic Healing Must...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial

Three Brain Injuries, One Iboga Protocol, and What It Tells Us

The War on Drugs Was Never About Drugs. Psychedelic Healing Must Reckon With That.

A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race

Complete Results from Red Light Oregon Market Research in Oregon Show...

Cybin Granted DEA Schedule I Manufacturing License

MINDCURE Provides Update on Studies and Clinical Trials

The Missing Mushroom: Psychedelic Science and the Future of Psilocybin

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy...

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker...

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion...

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development...

Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development...

EDITOR PICKS

Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA...

Three Brain Injuries, One Iboga Protocol, and What It Tells Us

The War on Drugs Was Never About Drugs. Psychedelic Healing Must...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY